37
Participants
Start Date
March 14, 2011
Primary Completion Date
February 11, 2017
Study Completion Date
February 11, 2017
Cisplatin
Given IV
Laboratory Biomarker Analysis
Correlative studies
Paclitaxel
Given IV
Veliparib
Given PO
Memorial Sloan Kettering Cancer Center, New York
Thomas Jefferson University Hospital, Philadelphia
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
University of Virginia Cancer Center, Charlottesville
Virginia Commonwealth University/Massey Cancer Center, Richmond
Medical University of South Carolina, Charleston
Augusta University Medical Center, Augusta
University of Mississippi Medical Center, Jackson
Singing River Hospital, Pascagoula
Ohio State University Comprehensive Cancer Center, Columbus
Riverside Methodist Hospital, Columbus
Case Western Reserve University, Cleveland
MetroHealth Medical Center, Cleveland
Hillcrest Hospital Cancer Center, Mayfield Heights
Cleveland Clinic Foundation, Cleveland
University of Iowa/Holden Comprehensive Cancer Center, Iowa City
University of Chicago Comprehensive Cancer Center, Chicago
Washington University School of Medicine, St Louis
University of Oklahoma Health Sciences Center, Oklahoma City
Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa
UT Southwestern/Simmons Cancer Center-Dallas, Dallas
M D Anderson Cancer Center, Houston
USC / Norris Comprehensive Cancer Center, Los Angeles
Women and Infants Hospital, Providence
Lyndon Baines Johnson General Hospital, Houston
Collaborators (1)
NRG Oncology
OTHER
National Cancer Institute (NCI)
NIH